Hai cercato la traduzione di entecavir da Inglese a Maltese

entecavir
entecavir

lamivudine abacavir entecavir
lamivudine

baraclude 1 mg tablets entecavir
baraclude 1 mg pilloli entecavir

the active substance is entecavir.
is-sustanza attiva hi entecavir.

each ml contains 0.05 mg entecavir.
kull ml fih 0.05 mg ta’ entecavir.

baraclude 0.05 mg/ml oral solution entecavir
baraclude 0.05 mg/ml soluzzjoni orali entecavir

baraclude 1 mg film-coated tablets entecavir
baraclude 1 mg pilloli miksijin b’rita entecavir

each ml of oral solution contains 0.05 mg entecavir.
kull ml ta’ soluzzjoni orali fih 0.05 mg ta’ entecavir.

each film-coated tablet contains 1 mg entecavir.
kull pillola miksija b’rita fiha 1 mg ta’ entecavir.

**on haemodialysis days, administer entecavir after haemodialysis.
** fi ġranet ta ’ emodijaliżi, agħti entecavir wara emodijaliżi.

each tablet contains 1 mg entecavir (as monohydrate).
kull pillola fiha 1 mg entecavir (bħala monoidrat).

the entecavir-tp ki for hbv dna polymerase is 0.0012 μm.
il-ki ta’ entecavir-tp għal polymerase tad-dna ta’ hbv huwa

the entecavir-tp ki for hbv dna polymerase is 0.0012 μ m.
il- ki ta ’ entecavir- tp għal polymerase tad- dna ta ’ hbv huwa 0. 0012 µm.

as entecavir is a nucleoside analogue, this risk cannot be excluded.
minħabba li entecavir huwa nucleoside analogue, dan ir-riskju ma jistax jiġi eskluż.

genotypic entecavir resistance through year 5, lamivudine-refractory studies
reżistenza Ġenotipika għal entecavir sa sena 5, studji dwar pazjenti refrattarji għal lamivudine

due to the metabolic pathway of entecavir, no clinically relevant drug-drug
minħabba l-passaġġ metaboliku ta’ entecavir, l-ebda interazzjoni klinikament rilevanti bejn mediċina u oħra mhi mistennija.

emerging genotypic entecavir resistance through year 5, nucleoside-naive studies
reżistenza Ġenotipika Ġdida għal entecavir sa sena 5, studji dwar pazjenti li qatt ma Ħadu nukleoside

emerging genotypic entecavir resistance through year 5, nucleoside-naive studies a
11 reżistenza Ġenotipika Ġdida għal entecavir sa sena 5, studji dwar pazjenti li qatt ma Ħadu nukleoside a

race: the population pharmacokinetic analysis did not identify race as significantly influencing entecavir pharmacokinetics.
razza: l-analiżi farmakokinetika tal-popolazzjoni ma wrietx li r-razza għandha effett b’mod sinifikanti fuq il-farmakokinetika ta’ entecavir.

absorption: entecavir is rapidly absorbed with peak plasma concentrations occurring between 0.5-
assorbiment: entecavir jiġi assorbit malajr, bl-ogħla konċentrazzjonijiet fil-plażma jseħħu bejn